Abstract
Cellular bio-energetic metabolism and mitochondria are recognized as potential targets for anticancer agents, due to the numerous relevant peculiarities cancer cells exhibit. Jasmonates are anticancer agents that interact directly with mitochondria. The aim of this study was to identify mitochondrial molecular targets of jasmonates. We report that jasmonates bind to hexokinase and detach it from the mitochondria and its mitochondrial anchor—the voltage-dependent anion channel (VDAC), as judged by hexokinase immunochemical and activity determinations, surface plasmon resonance analysis and planar lipid bilayer VDAC-activity analysis. Furthermore, the susceptibility of cancer cells and mitochondria to jasmonates is dependent on the expression of hexokinase, evaluated using hexokinase-overexpressing transfectants and its mitochondrial association. Many types of cancer cells exhibit overexpression of the key glycolytic enzyme, hexokinase, and its excessive binding to mitochondria. These characteristics are considered to play a pivotal role in cancer cell growth rate and survival. Thus, our findings provide an explanation for the selective effects of jasmonates on cancer cells. Most importantly, this is the first demonstration of a cytotoxic mechanism based on direct interaction between an anticancer agent and hexokinase. The proposed mechanism can serve to guide development of a new selective approach for cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Al jamal JA . (2005). Involvement of porin N,N-dicyclohexylcarbodiimide-reactive domain in hexokinase binding to the outer mitochondrial membrane. Protein J 24: 1–8.
Azoulay-Zohar H, Israelson A, Abu-hamad S, Shoshan-Barmatz V . (2004). In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 377: 347–355.
Boozer C, Kim G, Cong S, Guan H, Londergan T . (2006). Looking towards label-free biomolecular interaction analysis in a high-throughput format: a review of new surface plasmon resonance technologies. Curr Opin Biotechnol 17: 400–405.
Brawer MK . (2005). Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol 7: S21–S26.
Bustamante E, Pedersen PL . (1977). High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci USA 74: 3735–3739.
Chini A, Fonseca S, Fernendez G, Adie B, Chico JM, Lorenzo O et al. (2007). The JAZ family of repressors is the missing link in jasmonate signalling. Nature 448: 666–671.
Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H et al. (2002). The bioenergetic signature of cancer: A marker of tumor progression. Cancer Res 62: 6674–6681.
Dang CV, Semenza GL . (1999). Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68–72.
Debatin K-M, Poncet D, Kroemer G . (2002). Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21: 8786–8803.
Ehsani-Zonouz A, Golestani A, Nemat-Gorgani M . (2001). Interaction of hexokinase with the outer mitochondrial membrane and a hydrophobic matrix. Mol Cell Biochem 223: 81–87.
Fingrut O, Flescher E . (2002). Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia 16: 608–616.
Fingrut O, Reischer D, Rotem R, Goldin N, Altboum I, Zan-Bar I et al. (2005). Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells. Br J Pharmacol 146: 800–808.
Flescher E . (2005). Jasmonates—a new family of anti-cancer agents. Anticancer Drugs 16: 911–916.
Flescher E . (2007). Jasmonates in cancer therapy. Cancer Lett 245: 1–10.
Galuzzi L, Larochette N, Zamzami N, Kroemer G . (2006). Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25: 4812–4830.
Gincel D, Zaid H, Shoshan-Barmatz V . (2001). Calcium binding and translocation by the voltage-dependent anion channel: a possible regulatory mechanism in mitochondrial function. Biochem J 358: 147–155.
Goldin N, Heyfets A, Reischer D, Flescher E . (2007). Mitochondria-mediated ATP depletion by anti-cancer agents of the jasmonate family. J Bioenerg Biomemb 39: 51–57.
Green DR, Kroemer G . (2004). The pathophysiology of mitochondrial cell death. Science 305: 626–629.
Hamilton MD, Nuara AA, Gammon DB, Buller RM, Evans DH . (2007). Duplex strand joining reactions catalyzed by vaccinia virus DNA polymerase. Nucleic Acids Res 35: 143–151.
Hammerman PS, Fox CJ, Thompson CB . (2004). Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem Sci 29: 586–592.
Heyfets A, Flescher E . (2007). Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-d-glucose. Cancer Lett 50: 300–310.
Ishii Y, Kiyota H, Sakai S, Honma Y . (2004). Induction of differentiation of human myeloid leukemia cells by jasmonates, plant hormones. Leukemia 18: 1413–1419.
Isidoro A, Martinez M, Fernandez PL, Ortega AD, Santamaria G, Chamorro M et al. (2004). Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 378: 17–20.
Keisari Y . (1992). A colorimetric microtiter assay for the quantitation of cytokine activity on adherent cells in tissue culture. J Immunol Methods 146: 155–161.
Kroemer G . (2003). The mitochondrial permeability transition pore complex as a pharmacological target. An introduction. Curr Med Chem 10: 1469–1472.
Kroemer G . (2006). Mitochondria in cancer. Oncogene 25: 4630–4632.
Lampidis TJ, Kurtoglu M, Maher JC, Liu H, Krishan A, Sheft V et al. (2006). Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing ‘hypoxic tumor cells’. Cancer Chemother Pharmacol 58: 725–734.
Lemasters JJ, Nieminen A-L, Qian T, Trost LC, Elmore SP, Nishimura Y et al. (1998). The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366: 177–196.
Machida K, Ohta Y, Osada H . (2006). Supression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells. J Biol Chem 281: 14314–14320.
Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K et al. (2004). Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16: 819–830.
Mathupala SP, Ko YH, Pedersen PL . (2006). Hexokinase II: Cancer′s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777–4786.
Miccoli L, Beurdeley-Thomas A, De Oinieux G, Sureau F, Oudard S, Dutrillaux B et al. (1998). Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. Cancer Res 58: 5777–5786.
Nakashima RA, Mangan PS, Colombini M, Pedersen PL . (1986). Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N'-dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protin VDAC. Biochemistry 25: 1015–1021.
Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M et al. (1995). Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer 62: 216–222.
Pastorino JG, Hoek JB . (2003). Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem 10: 1535–1551.
Pastorino JG, Hoek JB, Shulga N . (2005). Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 15: 10545–10554.
Pedersen PL . (1978). Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 22: 190–274.
Pedersen PL . (2007a). The cancer cell's ‘power plants’ as promising therapeutic targets: an overview. J Bioenerg Biomembr 39: 1–12.
Pedersen PL . (2007b). Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the ‘Warburg Effect’, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39: 211–222.
Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH . (2002). Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 1355: 14–20.
Penso J, Beitner R . (2003). Lithium detaches hexokinase from mitochondria and inhibits proliferation of B16 melanoma cells. Mol Genet Metab 78: 74–78.
Reischer D, Heyfets A, Shimony S, Nordenberg J, Kashman Y, Flescher E . (2007). Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma. Br J Pharmacol 150: 738–749.
Robey RB, Hay N . (2005). Akt, hexokinase, mTOR: Targeting cellular energy metabolism for cancer therapy. Drug Discov Today Dis Mech 2: 239–246.
Robey RB, Hay N . (2006). Mitochondrial hexokinases, novel mediators of the antiapoptotic affects of growth factors and Akt. Oncogene 25: 4683–4696.
Rotem R, Heyfets A, Fingrut O, Blickstein D, Shaklai M, Flescher E . (2005). Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res 65: 1984–1993.
Shoshan-Barmatz V, Israelson A . (2005). The voltage-dependent anion channel in endoplasmic/sarcoplasmic reticulum: characterization, modulation and possible function. J Membr Biol 204: 57–66.
Sun L, Shukair S, Naik TJ, Moazed F, Ardehali H . (2008). Glucose phosphorylation and mitochondrial binding are required fir the protective effects of hexokinase I and II. Mol Cell Biol 28: 1007–1017.
Varbiro G, Veres B, Gallyas F, Sumegi B . (2001). Direct effect of Taxol on free redical formation and mitochondrial permeability transition. Free Radic Biol Med 31: 548–558.
Warburg O, Dickens F, Kaiser Wilhelm-Institut für Biologie B . (1930). The Metabolism of Tumours: Investigations from the Kaiser-Wilhelm Institute for Biology, Berlin-Dahlem. Constable: London.
Wilson JE . (1968). Brain hexokinase. J Biol Chem 243: 3640–3647.
Wilson JE . (1989). Rapid purification of mitochondrial hexokinase from rat brain by a single affinity chromatography step on Affi-Gel blue. Prep Biochem 19: 13–21.
Wilson JE . (1995). Hexokinases. Rev Physiol Biochem Pharmacol 126: 65–198.
Wilson JE . (2003). Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206: 2049–2057.
Wilson JE, Chung V . (1989). Rat brain hexokinase: Further studies on the specificity of the hexose and hexose 6-phosphate binding sites. Arch Biochem Biophys 269: 517–525.
Zaid H, Abu-Hamad S, Israelson A, Nathan I, Shoshan-Barmatz V . (2005). The voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death Differ 12: 751.
Acknowledgements
This work was supported in part by a grant from Sepal Pharma SA and by a grant from the Ministry of Science, Culture & Sport, Israel and the DKFZ Deutsches Krebsforschungszentrum, Germany, to EF.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Rights and permissions
About this article
Cite this article
Goldin, N., Arzoine, L., Heyfets, A. et al. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 27, 4636–4643 (2008). https://doi.org/10.1038/onc.2008.108
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.108
Keywords
This article is cited by
-
Apoptotic proteins with non-apoptotic activity: expression and function in cancer
Apoptosis (2023)
-
Protein synthesis inhibitors stimulate MondoA transcriptional activity by driving an accumulation of glucose 6-phosphate
Cancer & Metabolism (2020)
-
Salicylic acid-induced ROS production by mitochondrial electron transport chain depends on the activity of mitochondrial hexokinases in tomato (Solanum lycopersicum L.)
Journal of Plant Research (2019)
-
Methyl jasmonate ameliorates rotenone-induced motor deficits in rats through its neuroprotective activity and increased expression of tyrosine hydroxylase immunopositive cells
Metabolic Brain Disease (2019)
-
Mitochondrial metabolism and cancer
Cell Research (2018)